Anti-VEGF Prior Authorizations: Keeping Injection Patients on Schedule

Anti-VEGF therapy is uniquely unforgiving of administrative failure. The drugs are expensive enough that payers gate them aggressively, and the disease is unforgiving enough that a missed month can mean permanent vision loss. When a prior authorization lapses, the practice faces an ugly choice: inject and risk eating a four-figure drug cost, or delay treatment. A well-built auth system means never facing that choice.

Why anti-VEGF auths fail differently

Unlike a one-time surgical auth, anti-VEGF authorizations are recurring: they cover a set number of injections or a time window, then must be renewed — indefinitely, for a chronic disease. Each payer has different rules on duration, drug preference and step therapy, and documentation for continuation. The failure mode is rarely a denial; it's an expiration nobody was watching while the patient's every-8-weeks schedule marched on.

Build the auth calendar

The core tool is a tracking sheet (or PM report) with one row per active injection patient per eye: drug, payer, auth number, approval date, expiration date, injections approved, injections used. Two alarms drive everything:

• Renewal window alarm — opens 3–4 weeks before expiration, triggering the renewal submission with updated OCT findings and acuity data.
• Utilization alarm — fires when the patient is one injection away from exhausting the approved count, regardless of dates.

Review the full list weekly. The review takes twenty minutes and prevents the emergency that consumes a whole afternoon.

Master each payer's step-therapy logic

Most commercial payers and many Medicare Advantage plans require documented use of a preferred agent — typically off-label bevacizumab first — before covering branded drugs. For continuation and escalation requests, the winning documentation pattern is specific and quantitative: baseline and current OCT central subfield thickness, fluid status, visual acuity trend, and the clinical rationale for the requested agent. Template this per payer so the submission is assembly, not authorship.

Protect the revenue side too

Buy-and-bill practices carry serious inventory risk. Reconcile weekly: injections performed against auths on file against claims submitted against drug replacement orders. A single unbilled or denied injection of a branded agent can erase the margin on a week of visits. Denials for 'auth not on file' deserve same-week appeals with the approval documentation attached — they're usually payer matching errors and highly winnable.

Staff it deliberately

The auth calendar fails when it belongs to 'whoever has time.' High-volume retina practices give it a dedicated owner; smaller ophthalmology and optometry offices increasingly delegate it to a trained eye care virtual assistant who runs the tracker, submits renewals, and works the appeal queue at a flat $10/hour. The clinical team's job is medicine; the system's job is making sure paperwork never interrupts it. For the scheduling side of a smooth injection operation, see our injection clinic workflow guide.